First Patient dosed in Ph 1 Trial of IDE034
“This is an important milestone for IDE034 as well as our broader ADC/DDR portfolio focused on exploring combinations of highly selective TOP1 ADCs with agents targeting the DDR pathway. We are excited to begin dosing patients with IDE034, a B7H3/PTK7 bispecific ADC that has demonstrated promising signs of efficacy as a monotherapy and synergy in combination with IDE161 across several preclinical tumor cell models. IDE034 is our second proprietary TOP1 ADC, building on the progress we have made with IDE849, our DLL3 TOP1 ADC currently in Phase 1 for SCLC and NEC, and represents another potentially first-in-class therapy for cancer patients in need of new and improved treatment options,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines